A new analysis of the SURMOUNT-1 trial published in Diabetes, Obesity and Metabolism found that tirzepatide may help slow the decline in kidney function and reduce urine albumin levels in people with obesity and prediabetes. Over three years, participants showed better kidney markers compared with placebo, suggesting potential kidney-protective benefits.
Sponsored Advertisement
No comments yet. Be the first!